Investor Jim Chanos has joined the chorus that’s slamming Mallinckrodt Pharmaceuticals, which has been accused of price gouging by the likes of pharma bad boy Martin Shkreli.

Mallinckrodt’s premier drug Acthar, which is used to treat infantile spasms, “is the epitome of excessive drug pricing,” Chanos said Thursday in Las Vegas at the SkyBridge Alternatives Conference (SALT).

The cost of the drug jumped from $2,000 a vial to $23,000 in the space of 13 years, Chanos said. By the time Mallinckrodt acquired the company, the price had soared to $32,000, according to a company spokesman.

Rights to Acthar were acquired by Questcor in 2001 for a mere $100,000, Chanos said. Thirteen years later, Mallinckrodt acquired Questcor, whose main drug is Acthar, for $6 billion.

Shkreli tipped off the government to problems with Acthar in 2014, when he alleged in a lawsuit that Questcor engaged in anti-competitive tactics by buying lower-cost competing drug Synacthen, then yanking it from the market to boost the price of Acthar.

Earlier this year, Mallinck­rodt cut a $100 million settlement over the Synacthen deal with the Federal Trade Commission, which called it anti-competitive. Mallinckrodt didn’t admit to any wrongdoing.

In addition to Mallinckrodt, famed short-seller Chanos is also going after pharmacy benefits manager Express Scripts.

“The murky alliance between Mallinckrodt and Express Scripts has led to performance-enhancing drug prices. But could it give investors the blues?” Chanos said.

Several of the company’s subsidiaries are associated with Acthar, said Chanos, who frequently drew comparisons to scandal-ridden Valeant Pharmaceuticals.

Acthar is the “most expensive drug reimbursed by Medicare,” Chanos said. “We’re all paying for this.”

Lawmakers have voiced concerns on drug-price gouging, including Sen. Claire McCaskill (D-Mo.), whose state is where both Mallinckrodt and Express Scripts are based.

“Senator McCaskill, you’re from the Show-Me State. Why don’t you show us what you can do here?” Chanos said.